EU/3/14/1261: Orphan designation for the prevention of bronchopulmonary dysplasia

Caffeine citrate


On 11 April 2014, orphan designation (EU/3/14/1261) was granted by the European Commission to Viridian Pharma Ltd, United Kingdom, for caffeine citrate for the prevention of bronchopulmonary dysplasia.

Key facts

Active substance
Caffeine citrate
Intended use
Prevention of bronchopulmonary dysplasia
Orphan designation status
EU designation number
Date of designation
Viridian Pharma Ltd
Yew Tree House, Hendrew Lane
Llandevaud, Newport
Gwen, NP18 2AB
United Kingdom
Tel. +44 (0)163 3400 335
Fax +44 (0)163 3400 335

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating